Published in Law and Health Weekly, November 26th, 2005
Study 1: Researchers characterize soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by Semliki Forest virus in a recent issue of the Journal of Virology.
According to a study from Sweden and the United States, "The current lack of envelope glycoprotein immunogens that elicit broadly neutralizing antibody responses remains a major challenge for human immunodeficiency virus type 1 (HIV-1) vaccine development. However, the recent design and construction of stable soluble gp140 trimers have shown that some...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.